Aging, for so long treated as inevitable, is actually a problem to be solved.
A cluster of seven biotechnology and health startups, collectively backed by more than $460 million, has organized itself around a single audacious premise: that aging is not a destiny but a disease, and that science may soon offer a cure. From San Francisco to Boston to London, researchers and entrepreneurs are pursuing cellular reprogramming, gene therapy, epigenetic restoration, and AI-guided personal health — each path a different wager on the same question humanity has always asked about time and the body. Most of their therapies remain years from human hands, but the conviction driving them is already reshaping how medicine imagines the future.
- The race to defeat aging has moved from science fiction to venture capital, with $460 million already committed to companies that believe an extra decade of healthy life can become a purchasable reality.
- The most ambitious bets — cellular reprogramming at Retro Biosciences and epigenetic reversal at NewLimit — are still in animal studies or early trials, leaving a wide gap between the promise and what patients can actually access today.
- Meanwhile, Kyma Health and Tolion Health are already in users' pockets, deploying AI to analyze biomarkers and lifestyle data and deliver personalized longevity coaching without waiting for laboratory breakthroughs.
- Gene therapy from Genflow Biosciences, including a longevity gene found in centenarians, is advancing through clinical trials while simultaneously being tested in pets to accelerate understanding of the underlying biology.
- The supplement sector offers the only products available right now, but long-term human data remains sparse — meaning the most accessible longevity tools are also the least scientifically validated.
Siete empresas han decidido apostar por una idea que durante siglos pareció imposible: que el envejecimiento puede frenarse, detenerse o incluso revertirse. Algunas trabajan en laboratorios con terapias génicas y reprogramación celular. Otras han construido aplicaciones que analizan las señales del cuerpo en tiempo real. Todas comparten la misma convicción: que una década adicional de vida saludable puede convertirse en un producto, no en un milagro.
Retro Biosciences, fundada en San Francisco en 2021 con $180 millones recaudados, persigue tres vías terapéuticas simultáneas: reprogramar células a un estado más joven, inducir la autofagia mediante fármacos en lugar de ayuno, y explorar terapias basadas en plasma. La empresa también trabaja en reparar el daño al ADN y rejuvenecer células del sistema inmune. Entre sus inversores figura Sam Altman, CEO de OpenAI. Life Biosciences, con sede en Boston, apuesta por la reprogramación epigenética: su terapia más avanzada, ER-100, ha logrado regenerar nervios ópticos y mejorar la visión en estudios con animales, y actualmente se prueba contra el glaucoma.
No todas las startups operan en el laboratorio. Kyma Health analiza entre 80 y 100 biomarcadores para diseñar planes personalizados de dieta, sueño, ejercicio y suplementación, todo gestionado desde una app con coaching continuo. Tolion Health se enfoca en la salud cerebral: su aplicación Tolion Brain Coach procesa datos de wearables con modelos de lenguaje para ofrecer recomendaciones diarias que buscan reducir el riesgo de deterioro cognitivo.
Axia Longevity comercializa suplementos centrados en el NAD+, una coenzima clave para la energía celular y la reparación del ADN, aunque la evidencia a largo plazo en humanos sigue siendo limitada. Genflow Biosciences, empresa británica, desarrolla terapias génicas que incluyen el gen SIRT6 —presente en centenarios y vinculado al mantenimiento del ADN— administradas por vía intravenosa, con ensayos clínicos en curso y aplicaciones veterinarias en exploración. NewLimit, en California, va más lejos: con $280 millones recaudados y ensayos humanos en preparación, propone no solo frenar el envejecimiento sino revertirlo mediante inteligencia artificial y genómica unicelular.
En conjunto, estas siete empresas han captado más de $460 millones. La mayoría de sus terapias más ambiciosas tardarán años en llegar a los pacientes. Lo que las une no es solo el capital, sino una certeza compartida: que el envejecimiento, tratado durante milenios como inevitable, es en realidad un problema que puede resolverse.
Seven companies are betting that aging is not inevitable—that it can be slowed, stopped, or even reversed. Some are working in laboratories with gene therapy and cellular reprogramming. Others are building apps that sit in your pocket, analyzing your body's signals in real time. All of them are racing toward the same finish line: a future where an extra decade of healthy life is not a miracle, but a product you can buy.
Retro Biosciences, based in San Francisco, is perhaps the most ambitious. Since its founding in 2021, the company has raised $180 million to pursue a singular goal: adding ten years to human healthspan. The approach combines artificial intelligence with molecular biology and clinical trials, targeting the biological roots of age-related disease. The company is exploring three distinct therapeutic paths. One involves reprogramming cells to a younger state. Another focuses on autophagy—the body's natural cleaning process, normally triggered by fasting—but achieved through a drug rather than dietary restriction. A third works with plasma-based therapies. Beyond these, Retro is also attempting to repair DNA damage, rejuvenate immune cells in the brain, and regenerate stem cells in critical tissues. The ambition is to attack aging from multiple angles simultaneously. Sam Altman, the CEO of OpenAI, is among its investors, a signal of how seriously the technology world is taking the longevity space.
Life Biosciences, founded in Boston in 2017, is pursuing a different but related path: epigenetic reprogramming. The company believes that aging cells can be restored to a younger functional state without losing their identity or purpose. Its most advanced therapy, called ER-100, is being tested for diseases of the optic nerve, particularly glaucoma. In animal studies, the treatment has regenerated eye nerves and improved vision. The company's research spans mitochondrial function, cellular recycling mechanisms, and the epigenetic changes that accumulate over time.
Not all the startups are working in the laboratory. Kyma Health and Tolion Health have taken a more immediate, practical approach. Kyma begins with a comprehensive medical checkup, then layers artificial intelligence on top to design personalized health plans. The company analyzes between 80 and 100 biomarkers—measurable indicators of bodily function—to identify root causes of fatigue, digestive problems, hormonal imbalances, and metabolic dysfunction. From there, it prescribes customized adjustments to diet, sleep, exercise, and supplementation, all tracked through an app with ongoing coaching. Tolion takes a narrower focus: brain health. Its app, called Tolion Brain Coach, uses machine learning and large language models to process lifestyle data from wearables and deliver daily personalized recommendations aimed at reducing the risk of cognitive decline and neurodegenerative disease. The app includes a conversational AI assistant available around the clock to help users stick to their daily goals.
Axia Longevity is betting on supplements. The company has designed nutritional products intended to optimize cellular health, with particular focus on NAD+, a coenzyme essential for energy production and DNA repair. The company identifies twelve biomarkers most closely linked to aging and uses them to guide a preventive, personalized approach. The caveat is significant: many of the claimed benefits of such supplements remain under study, and long-term human data is sparse.
Genflow Biosciences, a British company, is developing gene therapies that deliver specially engineered genes—including SIRT6, a gene found in centenarians and associated with DNA maintenance and metabolic regulation—via intravenous infusion. The therapy is still in clinical trials. The company is also exploring veterinary applications, testing its approach on aging in pets to better understand the underlying biology.
NewLimit, based in California, represents perhaps the most radical proposition: not merely slowing aging, but reversing it. The company uses artificial intelligence, single-cell genomics, and computational biology to reprogram aged cells back to a youthful state. The founders believe that key tissues—the immune system, the liver—can be restored to younger function without harming the rest of the body. NewLimit has raised $280 million and is preparing to enter human trials in the coming years.
Together, these seven companies have raised more than $460 million. Most of their most ambitious therapies remain years away from human availability. The supplements are available now, but their long-term efficacy is unproven. The gene therapies and cellular reprogramming approaches are still in animal studies or early clinical trials. What unites them is a shared conviction: that aging, for so long treated as inevitable, is actually a problem to be solved.
Citas Notables
The ambition is to attack aging from multiple angles simultaneously.— Retro Biosciences' approach
The founders believe that key tissues like the immune system and liver can be restored to younger function without harming the rest of the body.— NewLimit's core thesis
La Conversación del Hearth Otra perspectiva de la historia
Why now? Why are so many companies attacking aging at the same time?
The tools finally exist. AI can process genetic data at scale. We can edit genes with precision. We understand the biology of aging better than ever. It's like the printing press arriving—suddenly the technology makes the problem solvable.
But most of these therapies won't be available for years. What's the business model in the meantime?
Some, like Kyma and Tolion, are selling apps and coaching today. They're profitable now. The others are betting on venture capital and the belief that whoever cracks this first will be worth billions. It's a long game.
Is there a risk that these companies are overpromising?
Absolutely. The supplement companies especially. We don't have long-term human data. But the gene therapy companies are being more careful—they're running proper clinical trials. The question is whether the science will match the hype.
If one of these therapies actually works, what happens to society?
Everything changes. Healthcare becomes preventive instead of reactive. Inequality could widen—if only the rich can afford an extra decade of health, that's a problem. But if it works and scales, aging as we know it might simply stop being the defining constraint of human life.
Which one do you think will succeed first?
Kyma or Tolion, probably. They're already helping people today. But the real breakthrough will come from Retro or NewLimit—if they can show in humans what they've shown in cells, the entire field shifts.